	<b>M04.3 - ONDANSETRON (ZOFRAN)</b>	
	Version date: 2025-01-30	Effective date: 2025-04-30 (07:00)



INDICATIONS
<ul style="list-style-type: none"> <li>Nausea and/or vomiting</li> </ul>

WARNINGS
<b>ABSOLUTE CONTRAINDICATIONS:</b> <ul style="list-style-type: none"> <li>Hypersensitivity to ondansetron</li> <li>Prolonged QT syndrome</li> <li>Do not administer with amiodarone or haloperidol</li> </ul>
<b>USE WITH CAUTION:</b> <ul style="list-style-type: none"> <li>Pregnancy</li> <li>History of serotonin syndrome <sup>1</sup></li> </ul>

ADMINISTRATION	
INTRAVENOUS (INTRAOSSEOUS)	ICP / ACP
<p>ADULTS / ADOLESCENTS:</p> <ul style="list-style-type: none"><li>• Administer 8 mg by slow push over 2 to 5 minutes</li><li>• Repeat every 4 hours as required</li></ul> <p>INFANTS / CHILDREN:</p> <ul style="list-style-type: none"><li>• Administer 0.15 to 0.3 mg/kg (maximum per dose = 8 mg) once</li><li>• No repeats</li></ul>	

NOTES
1. Serotonin syndrome has been reported with ondansetron administration in conjunction with fentanyl. Symptoms can include autonomic instability (tachycardia, fever, labile blood pressure); delirium, seizures, coma; and tremors, muscle rigidity, myoclonus and hyperreflexia.

LINKS
---

APPROVED BY	
	
Provincial Medical Director	Associate Provincial Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"> <li>• Addition of ACP work scope</li> <li>• Revised indication (removal of requirement for “not responsive to other antiemetics)</li> <li>• Revised contraindications / cautions</li> </ul>